Clinical Trial

AMT-253 in Patients With Advanced Solid Tumours

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-08; most recent amendment 2025-08-28.
Status change: Not Yet Recruiting → Recruiting 2024-03-14
Trial Details
NCT Number NCT06209580
Lead Sponsor Multitude Therapeutics Inc.
Conditions Malignant Melanoma, Advanced Solid Tumors
Enrollment 96 participants
Start Date 2024-01-31
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-05